Payment overview · 2025
General Payments
$4,786.38
199 reported records · 32 companies
Healthcare provider profile · identity verified
Vidal Primiterio, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LAWRENCE, MA · NPI 1861472987
Verified facts
What the public records show
CMS Open Payments records show Vidal Primiterio, PA received $4,786.38 in general payments during 2025 across 199 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,219.53 | 25.5% | 35 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $422.55 | 8.8% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $350.70 | 7.3% | 31 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $233.85 | 4.9% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $232.81 | 4.9% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $224.01 | 4.7% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $189.76 | 4.0% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $171.09 | 3.6% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $150.58 | 3.1% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $145.83 | 3.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.40 | 2.5% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $115.64 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $114.87 | 2.4% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $111.57 | 2.3% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $110.63 | 2.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $108.20 | 2.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $106.35 | 2.2% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.42 | 2.2% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $95.72 | 2.0% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $75.44 | 1.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $69.38 | 1.4% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.17 | 1.1% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $49.63 | 1.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.99 | 0.9% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $29.32 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.57 | 0.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.40 | 0.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.65 | 0.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.13 | 0.4% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $18.45 | 0.4% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.10 | 0.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.64 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,782.17 | 198 |
| Education | $4.21 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $490.43 | 19 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $422.55 | 11 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $264.77 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $246.53 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $229.23 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $224.16 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $224.01 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $215.56 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $210.14 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $189.76 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $174.55 | 11 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $150.58 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $145.83 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $128.67 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $115.64 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $111.57 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $110.63 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.35 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $106.35 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $104.42 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $97.51 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.27 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $85.88 | 13 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $85.88 | 13 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $82.05 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.97 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $69.38 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $69.33 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $62.65 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $57.53 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.67 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $49.63 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 47 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 104 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 115 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 180 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 160 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
47 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
160 | 53 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
180 | 56 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
180 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
128 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 34 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 827 | 280 |
| Metformin Hcl | Metformin Hcl | 618 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 611 | 193 |
| Lisinopril | Lisinopril | 585 | 175 |
| Omeprazole | Omeprazole | 574 | 183 |
| Gabapentin | Gabapentin | 441 | 141 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 378 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 101 |
| Metformin Hcl Er | Metformin Hcl | 330 | 132 |
| Ibuprofen | Ibuprofen | 302 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 80 |
| Glipizide | Glipizide | 275 | 88 |
| Januvia | Sitagliptin Phosphate | 275 | 79 |
| Losartan Potassium | Losartan Potassium | 262 | 83 |
| Simvastatin | Simvastatin | 235 | 78 |
| Meclizine Hcl | Meclizine Hcl | 223 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 217 | 80 |
| Trazodone Hcl | Trazodone Hcl | 207 | 77 |
| Atenolol | Atenolol | 183 | 53 |
| Jardiance | Empagliflozin | 180 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 58 |
| Furosemide | Furosemide | 171 | 59 |
| Citalopram Hbr | Citalopram Hydrobromide | 165 | 39 |
| Mirtazapine | Mirtazapine | 164 | 57 |
| Linzess | Linaclotide | 160 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 159 | 44 |
| Ezetimibe | Ezetimibe | 147 | 58 |
| Donepezil Hcl | Donepezil Hcl | 138 | 49 |
| Glipizide Er | Glipizide | 137 | 44 |
| Montelukast Sodium | Montelukast Sodium | 137 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 49 |
| Trulicity | Dulaglutide | 128 | 29 |
| Alendronate Sodium | Alendronate Sodium | 126 | 40 |
| Fenofibrate | Fenofibrate | 122 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 47 |
| Farxiga | Dapagliflozin Propanediol | 115 | 38 |
| Buspirone Hcl | Buspirone Hcl | 107 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 44 |
| Eliquis | Apixaban | 104 | 34 |
| Famotidine | Famotidine | 104 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 38 |
| Ammonium Lactate | Ammonium Lactate | 89 | 33 |
| Azithromycin | Azithromycin | 89 | 76 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 83 | 22 |
| Xarelto | Rivaroxaban | 81 | 18 |
| Meloxicam | Meloxicam | 75 | 39 |
| Hydrocortisone | Hydrocortisone | 71 | 31 |
| Prednisone | Prednisone | 71 | 56 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 24 |
| Ciclopirox | Ciclopirox | 68 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 18 |
| Carvedilol | Carvedilol | 64 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 64 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 52 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 55 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 14 |
| Irbesartan | Irbesartan | 50 | 15 |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 48 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 48 | suppressed |
| Creon | Lipase/Protease/Amylase | 47 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 39 |
| Finasteride | Finasteride | 46 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 16 |
| Dexamethasone | Dexamethasone | 43 | 41 |
| Labetalol Hcl | Labetalol Hcl | 43 | suppressed |
| Pregabalin | Pregabalin | 41 | 11 |
| Valsartan | Valsartan | 41 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 22 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 13 |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 31 |
| Nystatin | Nystatin | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 17 |
| Alcohol Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | 12 |
| Levofloxacin | Levofloxacin | 27 | 26 |
| Lidocaine | Lidocaine | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Kerendia | Finerenone | 26 | 11 |
| Lorazepam | Lorazepam | 26 | 18 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 11 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Naproxen | Naproxen | 23 | 13 |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,786.38 · 199 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, APTIMA, AREXVY, BREZTRI, CAMZYOS, COMIRNATY, CREON, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, FUROSCIX, GEMTESA, GVOKE HYPOPEN, IBSRELA, INSPIRE, JARDIANCE, JOURNAVX, KISUNLA, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, Veozah, WAINUA, XIFAXAN, YUPELRI, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error